CIK 0001400118 · <br>Emerging growth company
Sagimet Biosciences Inc.
Sign in to watch- Ticker
- SGMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205991472
- Phone
- (650) 561-8600
- Business address
- 950 TOWER LANE, STE 1500, FOSTER CITY, CA, 94404
- Former names
- 3-V Biosciences, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-18 | Parsey Merdad Director | Returned to the company · Stock Option (Right to Buy) | −23,216 | 0 | ||
| 2023-07-18 | Parsey Merdad Director | Grant or award · Stock Option (Right to Buy) | +23,216 | 23,216 | ||
| 2023-07-18 | Parsey Merdad Director | Returned to the company · Stock Option (Right to Buy) | −23,839 | 0 | ||
| 2023-07-18 | Parsey Merdad Director | Grant or award · Stock Option (Right to Buy) | +23,839 | 23,839 | ||
| 2023-07-18 | Martins Eduardo Bruno Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −198,132 | 0 | ||
| 2023-07-18 | Martins Eduardo Bruno Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +198,132 | 198,132 | ||
| 2023-07-18 | Martins Eduardo Bruno Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −44,009 | 0 | ||
| 2023-07-18 | Martins Eduardo Bruno Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +44,009 | 44,009 | ||
| 2023-07-18 | Kemble George Director | Returned to the company · Stock Option (Right to Buy) | −5,630 | 0 | ||
| 2023-07-18 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +5,630 | 5,630 | ||
| 2023-07-18 | Kemble George Director | Returned to the company · Stock Option (Right to Buy) | −3,179 | 0 | ||
| 2023-07-18 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +3,179 | 3,179 | ||
| 2023-07-18 | Kemble George Director | Returned to the company · Stock Option (Right to Buy) | −7,147 | 0 | ||
| 2023-07-18 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +7,147 | 7,147 | ||
| 2023-07-18 | Kemble George Director | Returned to the company · Stock Option (Right to Buy) | −26,352 | 0 | ||
| 2023-07-18 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +26,352 | 26,352 | ||
| 2023-07-18 | Kemble George Director | Returned to the company · Stock Option (Right to Buy) | −367,824 | 0 | ||
| 2023-07-18 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +367,824 | 367,824 | ||
| 2023-07-18 | Kemble George Director | Returned to the company · Stock Option (Right to Buy) | −46,432 | 0 | ||
| 2023-07-18 | Kemble George Director | Grant or award · Stock Option (Right to Buy) | +46,432 | 46,432 |
Page 9 of 10 · 194 trades